GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procaps Group SA (NAS:PROC) » Definitions » Gross Margin %

Procaps Group (Procaps Group) Gross Margin % : 57.77% (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Procaps Group Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Procaps Group's Gross Profit for the three months ended in Sep. 2023 was $68.4 Mil. Procaps Group's Revenue for the three months ended in Sep. 2023 was $118.4 Mil. Therefore, Procaps Group's Gross Margin % for the quarter that ended in Sep. 2023 was 57.77%.


The historical rank and industry rank for Procaps Group's Gross Margin % or its related term are showing as below:

PROC' s Gross Margin % Range Over the Past 10 Years
Min: 55.04   Med: 57.63   Max: 58.44
Current: 55.04


During the past 4 years, the highest Gross Margin % of Procaps Group was 58.44%. The lowest was 55.04%. And the median was 57.63%.

PROC's Gross Margin % is ranked better than
64.06% of 985 companies
in the Drug Manufacturers industry
Industry Median: 47 vs PROC: 55.04

Procaps Group had a gross margin of 57.77% for the quarter that ended in Sep. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Procaps Group was 0.00% per year.


Procaps Group Gross Margin % Historical Data

The historical data trend for Procaps Group's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Procaps Group Gross Margin % Chart

Procaps Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Gross Margin %
56.19 57.72 57.53 58.44

Procaps Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.19 51.50 54.73 55.60 57.77

Competitive Comparison of Procaps Group's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Procaps Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Procaps Group's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procaps Group's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Procaps Group's Gross Margin % falls into.



Procaps Group Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Procaps Group's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )=Gross Profit (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=239.6 / 409.92
=(Revenue - Cost of Goods Sold) / Revenue
=(409.92 - 170.351) / 409.92
=58.44 %

Procaps Group's Gross Margin for the quarter that ended in Sep. 2023 is calculated as


Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=68.4 / 118.41
=(Revenue - Cost of Goods Sold) / Revenue
=(118.41 - 50.007) / 118.41
=57.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Procaps Group  (NAS:PROC) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Procaps Group had a gross margin of 57.77% for the quarter that ended in Sep. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Procaps Group Gross Margin % Related Terms

Thank you for viewing the detailed overview of Procaps Group's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Procaps Group (Procaps Group) Business Description

Traded in Other Exchanges
Address
9 Rue de Bitbourg, Luxembourg, LUX, L-1273
Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.
Executives
Alexandre Weinstein Manieu director, 10 percent owner CHASHAM PLACE, FLAT 1, LONDON X0 SW1X 8HG
Ruben Minski director, 10 percent owner, officer: Chief Executive Officer 9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Jose Minski director, 10 percent owner 9 RUE DE BITBOURG, C/O PROCAPS GROUP, S.A., LUXEMBOURG N4 L-1273
Sognatore Trust 10 percent owner OFICINA 503A-02, EDIFICIO QUANTUM, (500) RUTA 8 KM. 17.500 ZONAMERICA, MONTEVIDEO X3 91600
Simphony Trust 10 percent owner 29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Deseja Trust 10 percent owner 29 BANCROFT MILLS ROAD, WILMINGTON DE 19806
Hoche Partners Pharma Holding S.a. 10 percent owner 3A VAL SAINTE CROIX, LUXEMBOURG N4 L-1371